GLAUKOS Corp: insider trades · United States · SEC (Form 4)

About GLAUKOS Corp

Glaukos Corp. (ticker: GKOS) is a United States-based ophthalmic medical technology and pharmaceutical company listed on the New York Stock Exchange (NYSE). Its global headquarters is in Aliso Viejo, California, United States. Founded in 1998, Glaukos has built its business around therapies for glaucoma, corneal disorders, and retinal diseases, positioning itself at the intersection of medical devices, procedural eye care, and ophthalmic pharmaceuticals. ([glaukos.com](https://www.glaukos.com/wp-content/uploads/2025/04/Glaukos-2024-Sustainability-Report-04162025-REVISED.pdf)) The company’s original breakthrough was in Micro-Invasive Glaucoma Surgery (MIGS), an alternative to the traditional glaucoma treatment paradigm. Glaukos launched its first MIGS device commercially in 2012, establishing an early and differentiated franchise in minimally invasive ophthalmic procedures. Over time, that innovation-led model broadened into a multi-platform strategy that combines devices, drug delivery, and corneal therapeutics rather than relying on a single product category. ([investors.glaukos.com](https://investors.glaukos.com/news/news-details/2025/Glaukos-to-Celebrate-10th-Anniversary-of-IPO-Listing-with-NYSE-Closing-Bell/default.aspx)) Today, Glaukos’ core commercial and development portfolio includes the iStent family for glaucoma, iDose TR, a long-duration intracameral drug-delivery platform for glaucoma, and Photrexa/Epioxa for corneal cross-linking in keratoconus. The company stated that iDose TR entered commercial launch activities in 2024, while Epioxa received FDA approval in October 2025 and became commercially available in March 2026. Glaukos also highlights a pipeline of follow-on programs and next-generation ophthalmic candidates, supporting the view that the business is still in a platform-expansion phase. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001192448/000110465926003321/gkos-20260113xex99d1.htm)) From a competitive standpoint, Glaukos occupies a strong niche in ophthalmology thanks to its proprietary technology, regulatory depth, and long-standing relationships with eye-care specialists. It is widely viewed as a category leader in MIGS and a meaningful innovator in corneal care. The company has a global commercial footprint, with direct operations in the United States, Canada, the United Kingdom, Germany, Japan, Australia, and Brazil, which helps diversify its revenue base beyond its home market. ([glaukos.com](https://www.glaukos.com/wp-content/uploads/2025/04/Glaukos-2024-Sustainability-Report-04162025-REVISED.pdf)) Recent developments have been particularly important. In January 2026, Glaukos reported preliminary full-year 2025 net sales of about $507 million, up roughly 32% year over year, and reiterated 2026 revenue guidance of $600 million to $620 million. The company also announced in September 2025 that it had broken ground on a new research, development, and manufacturing facility in Huntsville, Alabama, backed by an investment of more than $80 million, underlining its commitment to U.S. manufacturing capacity. In our view, these events reinforce the company’s transition from a single-franchise ophthalmology innovator into a broader, commercially scaled platform company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001192448/000110465926003321/gkos-20260113xex99d1.htm))